Mirdametinib with vinblastine chemotherapy for newly diagnosed PLGG
Original title: Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, and part of it is still working out the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug taken by mouth, mirdametinib, given together with vinblastine chemotherapy in people with newly diagnosed PLGG.
Who this trial is for. This trial is for people with PLGG whose tumor shows activation of the MAPK pathway, and who have not been treated for it yet. It is testing mirdametinib, taken by mouth, along with vinblastine chemotherapy given through a vein.
Where it stands. There are no results yet. The first part of the trial is working out the dose people can take. Then patients get the two drugs together for a set number of cycles. After treatment ends, people come back for a visit every 6 months for 36 months so the team can track how they do. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, or your child's, you could ask your care team about it. They know the details of the case and can say whether it is worth looking into. A trial is one way a drug that is still being studied can be tried, with close monitoring.
What it doesn't mean: This does not mean this drug pairing works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure. It is also not a promise of a spot in the study. The trial team decides who can join.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.